SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1181GS: AMGN(OP/N): Beat Q1 & raised guidance. Maint. est. and OP. Pipeline moremopgcw-4/22/2005
1180Merrill: Amgen Inc (AMGN, $59.25, C-1-9) Reiterate Buy and $77 PT. Q1 Results: tom pope-4/22/2005
1179Good enough revenue for me. I added to my few shares. Jmo, and I have been wroPaul Senior-4/21/2005
1178AMGN earnings - not a very good AH reaction, tho. I guess they would have prefertom pope-4/21/2005
1177Message 21247013mopgcw-4/20/2005
1176SSB: OPINION We provide a summary of key takeaways from our Smith Barney Healthmopgcw-4/5/2005
1175Treatment with ENBREL Had a Positive Effect on Activities of Daily Living for Pazax-2/18/2005
1174Amgen Will Halt Trials Of Parkinson's Drug DOW JONES NEWSWIRES February 14,mopgcw-2/14/2005
1173GS: AMGN(OP/N): Missed Q4 on higher costs. Guidance conservative. Maintain est Amopgcw-2/3/2005
1172if you own one of those bonds, you can put it to amgn by march 1st.mopgcw-2/1/2005
1171Can anyone explain what is the following news about, please? Amgen Announces PuXpiderman-1/31/2005
1170Amgen Inc. EPS (FY Dec) 2004E $2.43, 2005E $2.85 Outperform/Neutral (AMGN) $63.5mopgcw-1/28/2005
1169SSB : Amgen (AMGN, Buy, Medium Risk) Reporting date: Thursday, January 27th, bmopgcw-1/27/2005
1168GS: AMGN (OP/N): Minor impact from warnings in Aranesp label 52-Week Range US$6mopgcw-1/17/2005
1167AMGN named Forbes Company Of The Year As part of the "Special Report on AmRay Rueb-1/7/2005
1166Enbrel production will ramp up in 2005 From AMGN's website: See Amgen Sept Ray Rueb-12/18/2004
1165What I heard is that Amgen cannot make enough Enbrel to supply the market. Can Xpiderman-12/17/2004
1164AMGN's Enbrel competes with PFE's Celebrex for RA Does anyone think PFERay Rueb-12/17/2004
1163Here's a nice addition from Amgen's pipeline! Merry Christmas! THOUSAsteve kammerer-12/15/2004
1162GS: ASH review - AMGN`s pipeline progresses. More data needed on Rituxan maintenmopgcw-12/6/2004
1161GS: AMGN (OP/N): Timing for European guidelines on biogenerics in line. 52-Weekmopgcw-11/30/2004
1160GS: AMGN (OP/N): 1st take: Beat Q3 by 2c. Aranesp light due to discounts Annualmopgcw-10/25/2004
1159gs: This morning, the UK's House of Lords ruled against AMGN in its patent smopgcw-10/25/2004
1158GS: AMGN shares were weak after the Q3 earnings call partly due to renewed invesmopgcw-10/25/2004
1157GS: Amgen Inc. EPS (FY Dec) 2004E $2.42, 2005E $2.85 Outperform/Neutral (AMGN) $mopgcw-10/25/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News